Peter Kaiser, the Chief Development Officer of $OCUL, sold 3,011 shares of the company on 08-25-2025 for an estimated $36,252. We received data on the trade from a recent SEC filing. This was a sale of approximately 1.5% of their shares of this class of stock. Following this trade, they now own 204,093 shares of this class of $OCUL stock.
$OCUL Insider Trading Activity
$OCUL insiders have traded $OCUL stock on the open market 10 times in the past 6 months. Of those trades, 1 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $OCUL stock by insiders over the last 6 months:
- PRAVIN DUGEL (See Remarks) has made 0 purchases and 2 sales selling 42,713 shares for an estimated $411,140.
- NADIA WAHEED (Chief Medical Officer) sold 13,861 shares for an estimated $111,581
- RICHARD L MD LINDSTROM purchased 10,000 shares for an estimated $69,600
- JEFFREY S. HEIER (Chief Scientific Officer) has made 0 purchases and 2 sales selling 6,087 shares for an estimated $58,590.
- PETER KAISER (Chief Development Officer) has made 0 purchases and 2 sales selling 5,985 shares for an estimated $57,576.
- SANJAY NAYAK (Chief Strategy Officer) has made 0 purchases and 2 sales selling 3,747 shares for an estimated $36,045.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$OCUL Hedge Fund Activity
We have seen 95 institutional investors add shares of $OCUL stock to their portfolio, and 92 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 18,666,877 shares (+1983.1%) to their portfolio in Q2 2025, for an estimated $173,228,618
- OCTAGON CAPITAL ADVISORS LP added 2,129,000 shares (+719.3%) to their portfolio in Q2 2025, for an estimated $19,757,120
- PARADIGM BIOCAPITAL ADVISORS LP added 2,106,322 shares (+160.3%) to their portfolio in Q2 2025, for an estimated $19,546,668
- BLACKROCK, INC. removed 1,466,018 shares (-12.2%) from their portfolio in Q2 2025, for an estimated $13,604,647
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 1,349,159 shares (+307.0%) to their portfolio in Q2 2025, for an estimated $12,520,195
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 1,309,823 shares (-25.2%) from their portfolio in Q2 2025, for an estimated $12,155,157
- PERCEPTIVE ADVISORS LLC removed 915,775 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $8,498,392
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$OCUL Analyst Ratings
Wall Street analysts have issued reports on $OCUL in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 08/05/2025
- HC Wainwright & Co. issued a "Buy" rating on 05/29/2025
- William Blair issued a "Outperform" rating on 04/08/2025
- RBC Capital issued a "Outperform" rating on 03/18/2025
- Citizens Capital Markets issued a "Market Outperform" rating on 03/04/2025
To track analyst ratings and price targets for $OCUL, check out Quiver Quantitative's $OCUL forecast page.
$OCUL Price Targets
Multiple analysts have issued price targets for $OCUL recently. We have seen 5 analysts offer price targets for $OCUL in the last 6 months, with a median target of $17.0.
Here are some recent targets:
- Greg Harrison from Scotiabank set a target price of $20.0 on 08/06/2025
- Serge Belanger from Needham set a target price of $15.0 on 08/05/2025
- Yi Chen from HC Wainwright & Co. set a target price of $15.0 on 05/29/2025
- Luca Issi from RBC Capital set a target price of $17.0 on 03/18/2025
- Jonathan Wolleben from Citizens Capital Markets set a target price of $19.0 on 03/04/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
